menaquinone-7What was measured
Measured, with no finding
417 endpoints
Show what was measuredHide what was measured
bone markers and coagulation parameters
no effect
In both groups, bone markers and coagulation parameters remained constant over time
PMID 19450370 · one of two readings recorded this
circulating undercarboxylated osteocalcin, carboxylated osteocalcin, ucOC:cOC ratio and serum MK-7 in healthy prepubertal children
decreases, n = 28
Not recorded as a finding: the result compares a group with itself, not with a control
In the MK-7-supplemented group (n 28), the circulating concentration of inactive ucOC reduced and the UCR improved whereas the concentration of MK-7 increased.
PMID 19450370 · one of two readings recorded this
circulating undercarboxylated osteocalcin (ucOC), carboxylated osteocalcin and ucOC:cOC ratio, serum, 8 weeks
decreases, n = 28
Not recorded as a finding: the result compares a group with itself, not with a control
In the MK-7-supplemented group (n 28), the circulating concentration of inactive ucOC reduced and the UCR improved whereas the concentration of MK-7 increased.
PMID 19450370 · one of two readings recorded this
serum ucOC, UCR and MK-7 concentration
modulates, n = 28
In the MK-7-supplemented group (n 28), the circulating concentration of inactive ucOC reduced and the UCR improved whereas the concentration of MK-7 increased
PMID 19450370 · one of two readings recorded this
serum undercarboxylated and carboxylated osteocalcin (ucOC:cOC ratio) and serum MK-7 concentration
increases, MK-7 supplementation increased circulating MK-7 and osteocalcin carboxylation
Not recorded as a finding: this platform holds no node for the endpoint
These findings demonstrate that in healthy, prepubertal children, modest supplementation with MK-7 increases circulating concentrations of MK-7 and increases osteocalcin carboxylation.
PMID 19450370 · one of two readings recorded this
serum undercarboxylated osteocalcin, carboxylated osteocalcin and ucOC:cOC ratio (UCR) in healthy prepubertal children
decreases
Not recorded as a finding: this platform holds no node for the endpoint
In the MK-7-supplemented group (n 28), the circulating concentration of inactive ucOC reduced and the UCR improved whereas the concentration of MK-7 increased.
PMID 19450370 · one of two readings recorded this
ucOC, cOC, UCR and MK-7
no effect
Within the placebo group, ucOC, cOC, UCR and MK-7 did not significantly change over time
PMID 19450370 · one of two readings recorded this
bone loss rate (bone mineral density change), femoral neck
no effect
After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.
PMID 19937427 · one of two readings recorded this
bone loss rate (bone mineral density change), lumbar spine
no effect
After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.
PMID 19937427 · one of two readings recorded this
bone loss rate (bone mineral density change), total body
no effect
After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.
PMID 19937427 · one of two readings recorded this
bone loss rate (bone mineral density change), total hip
no effect
After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.
PMID 19937427 · one of two readings recorded this
bone mineral density change (bone loss rate), femoral neck, 12 months; instrument not named in abstract
no effect
Not recorded as a finding: CAT:outcome/femoral-neck-bmd exists, but the result sentence covers the femoral neck only as 'any other measurement site', so no object span names it; the node also requires DXA, which the abstract never states
After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.
PMID 19937427 · one of two readings recorded this
bone mineral density change (bone loss rate), lumbar spine, 12 months; instrument not named in abstract
no effect
Not recorded as a finding: CAT:outcome/lumbar-spine-bmd exists, but the result sentence covers the lumbar spine only as 'any other measurement site', so no object span names it; the node also requires DXA and states vertebral levels, neither given in the abstract
After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.
PMID 19937427 · one of two readings recorded this
bone mineral density change (bone loss rate), total body, 12 months; instrument not named in abstract
no effect
Not recorded as a finding: no outcome node for total-body BMD; the result sentence names it only as 'any other measurement site'
After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.
PMID 19937427 · one of two readings recorded this
bone mineral density change (bone loss rate), total hip, 12 months; instrument not named in abstract
no effect
Not recorded as a finding: no outcome node for total hip BMD; the only result sentence also does not name the compound, only 'between the groups'
After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.
PMID 19937427 · one of two readings recorded this
carboxylated osteocalcin (cOC)
increases, p = 0.001
Serum levels of cOC increased and ucOC decreased in the treatment versus the placebo group (p < 0.001).
PMID 19937427 · one of two readings recorded this
femoral neck bone mineral density, rate of bone loss over 12 months
no effect
Not recorded as a finding: CAT:outcome/femoral-neck-bmd exists, but the only between-group sentence names the total hip and 'any other measurement site'; femoral neck is not in that sentence, so the object span cannot be anchored without a second (measurement-site) sentence. The abstract also does not state the DXA scanner the node records
After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.
PMID 19937427 · one of two readings recorded this
lumbar spine bone mineral density, rate of bone loss over 12 months
no effect
Not recorded as a finding: CAT:outcome/lumbar-spine-bmd exists, but the only between-group sentence names the total hip and 'any other measurement site'; lumbar spine is not in that sentence, so the object span cannot be anchored without a second (measurement-site) sentence. Vertebral levels are not stated in the abstract
After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.
PMID 19937427 · one of two readings recorded this
serum carboxylated osteocalcin (cOC), assay not named in abstract
increases
Not recorded as a finding: no outcome node: CAT:outcome/serum-undercarboxylated-osteocalcin covers the undercarboxylated fraction only; no node for carboxylated osteocalcin
Serum levels of cOC increased and ucOC decreased in the treatment versus the placebo group (p < 0.001).
PMID 19937427 · one of two readings recorded this
serum carboxylated osteocalcin (cOC)
increases
Not recorded as a finding: no outcome node for carboxylated osteocalcin; CAT:outcome/serum-undercarboxylated-osteocalcin is the undercarboxylated form only, a different analyte
Serum levels of cOC increased and ucOC decreased in the treatment versus the placebo group (p < 0.001).
PMID 19937427 · one of two readings recorded this
total body bone mineral density, rate of bone loss over 12 months
no effect
Not recorded as a finding: no outcome node for total body BMD; and the sentence covers it only as 'any other measurement site'
After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.
PMID 19937427 · one of two readings recorded this
total hip bone mineral density, rate of bone loss over 12 months
no effect
Not recorded as a finding: no outcome node for total hip BMD; CAT:outcome/femoral-neck-bmd is the femoral neck region of interest only, a different site
After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.
PMID 19937427 · one of two readings recorded this
under-carboxylated osteocalcin (ucOC)
decreases, p = 0.001
Serum levels of cOC increased and ucOC decreased in the treatment versus the placebo group (p < 0.001).
PMID 19937427 · one of two readings recorded this
L2 to L4 bone mineral content
no effect, p = 0.5
the difference between vitamin K2 and placebo for the lumbar spine (L2-L4) bone mineral density (BMD) was 0.028 (SE 0.014) g/cm(2), P=0.055 and for L2 to L4 bone mineral content was 1.33 (SE 1.91) g/cm(2) (P=0.5)
PMID 20177349 · one of two readings recorded this
L2 to L4 bone mineral content
no effect, p = 0.9
In lung recipients separately, the difference for bone mineral content was 3.39 g (SE 1.65), P=0.048 and in heart recipients 0.45 (SE 0.02) g, P=0.9 after controlling for baseline measures.
PMID 20177349 · one of two readings recorded this
L2 to L4 bone mineral content
increases, p = 0.048
In lung recipients separately, the difference for bone mineral content was 3.39 g (SE 1.65), P=0.048 and in heart recipients 0.45 (SE 0.02) g, P=0.9 after controlling for baseline measures.
PMID 20177349 · one of two readings recorded this
lumbar spine (L2-L4) bone mineral density
increases, p = 0.019
fitted to model differences in the L2 to L4 BMD, controlled for possible confounding variables (including use of bisphosphonate), and the only significant predictors were organ (B=-0.065 g/cm(2), P<0.001) and vitamin K2 (B=0.034 g/cm(2), P=0.019)
PMID 20177349 · one of two readings recorded this
lumbar spine (L2-L4) bone mineral density
increases, p = 0.055
In all recipients, 1 year after solid organ transplantation, the difference between vitamin K2 and placebo for the lumbar spine (L2-L4) bone mineral density (BMD) was 0.028 (SE 0.014) g/cm(2), P=0.055
PMID 20177349 · one of two readings recorded this
lumbar spine (L2-L4) bone mineral density
unclear, p = 0.001
fitted to model differences in the L2 to L4 BMD, controlled for possible confounding variables (including use of bisphosphonate), and the only significant predictors were organ (B=-0.065 g/cm(2), P<0.001) and vitamin K2 (B=0.034 g/cm(2), P=0.019)
PMID 20177349 · one of two readings recorded this
parathyroid hormone
increases
Insufficient vitamin D status was common, and the parathyroid hormone was highest in the K2 group indicating a higher need for vitamin D.
PMID 20177349 · one of two readings recorded this
carboxylation of circulating matrix Gla-protein (dp-ucMGP)
increases
MK-7 supplementation at doses in the order of the RDA (Commission Directive 2008/100/EC) increased the carboxylation of circulating OC and MGP
PMID 22289649 · one of two readings recorded this
carboxylation of circulating osteocalcin and matrix Gla protein (ucOC, cOC, dp-ucMGP by ELISA; ucOC:cOC ratio) and thrombin generation by calibrated automated thrombography
increases
Not recorded as a finding: this platform holds no node for the endpoint
MK-7 supplementation at doses in the order of the RDA (Commission Directive 2008/100/EC) increased the carboxylation of circulating OC and MGP.
PMID 22289649 · one of two readings recorded this
carboxylation of circulating osteocalcin and matrix Gla protein (ucOC:cOC ratio, desphospho-uncarboxylated MGP), ELISA
increases
Not recorded as a finding: this platform holds no node for the endpoint
MK-7 supplementation at doses in the order of the RDA (Commission Directive 2008/100/EC) increased the carboxylation of circulating OC and MGP.
PMID 22289649 · one of two readings recorded this
carboxylation of circulating osteocalcin and matrix Gla protein (ucOC:cOC ratio, dp-ucMGP by ELISA); endogenous thrombin potential and peak height by calibrated automated thrombography
increases, increased carboxylation of circulating OC and MGP at doses around the RDA
Not recorded as a finding: this platform holds no node for the endpoint
MK-7 supplementation at doses in the order of the RDA (Commission Directive 2008/100/EC) increased the carboxylation of circulating OC and MGP.
PMID 22289649 · one of two readings recorded this
carboxylation of circulating osteocalcin and matrix Gla protein (ucOC:cOC ratio, dp-ucMGP), ELISA; endogenous thrombin potential by calibrated automated thrombography
increases
Not recorded as a finding: this platform holds no node for the endpoint
MK-7 supplementation at doses in the order of the RDA (Commission Directive 2008/100/EC) increased the carboxylation of circulating OC and MGP.
PMID 22289649 · one of two readings recorded this
carboxylation of circulating osteocalcin (ucOC:cOC ratio)
increases
MK-7 supplementation at doses in the order of the RDA (Commission Directive 2008/100/EC) increased the carboxylation of circulating OC and MGP
PMID 22289649 · one of two readings recorded this
endogenous thrombin potential and peak height
no effect
No adverse effects on thrombin generation were observed
PMID 22289649 · one of two readings recorded this
change in serum 25(OH)D
increases, p = 0.01
The increase observed for serum 25(OH)D levels in all intervention groups and the increase observed for serum IGF-I levels in the CaDK2 group differed significantly compared to the changes observed in CG (P = 0.010 and P = 0.028, respectively)
PMID 22392526 · one of two readings recorded this
change in serum IGF-I
increases, p = 0.028
The increase observed for serum 25(OH)D levels in all intervention groups and the increase observed for serum IGF-I levels in the CaDK2 group differed significantly compared to the changes observed in CG (P = 0.010 and P = 0.028, respectively)
PMID 22392526 · one of two readings recorded this
lumbar spine BMD
increases, p = 0.05
significant increases in lumbar spine BMD were observed only for CaDK1 and CaDK2 compared to CG (P < 0.05)
PMID 22392526 · one of two readings recorded this
serum IGF-I, serum 25(OH)D, lumbar spine and total-body BMD, ucOC/OC ratio, urine deoxypyridinoline
increases, p = 0.028
Not recorded as a finding: the intervention held more than the compound
The increase observed for serum 25(OH)D levels in all intervention groups and the increase observed for serum IGF-I levels in the CaDK2 group differed significantly compared to the changes observed in CG (P = 0.010 and P = 0.028, respectively).
PMID 22392526 · one of two readings recorded this
serum undercarboxylated osteocalcin to osteocalcin ratio
decreases, p = 0.001
both the CaDK1 and CaDK2 groups had a significantly lower mean serum undercarboxylated osteocalcin to osteocalcin ratio and urine deoxypyridinoline levels at follow-up compared to the CaD and CG groups (P = 0.001 and P = 0.047, respectively)
PMID 22392526 · one of two readings recorded this
total-body BMD
increases, p = 0.05
Significant increases in total-body BMD were observed in all intervention groups compared to CG (P < 0.05)
PMID 22392526 · one of two readings recorded this
urine deoxypyridinoline
decreases, p = 0.047
both the CaDK1 and CaDK2 groups had a significantly lower mean serum undercarboxylated osteocalcin to osteocalcin ratio and urine deoxypyridinoline levels at follow-up compared to the CaD and CG groups (P = 0.001 and P = 0.047, respectively)
PMID 22392526 · one of two readings recorded this
circulating desphospho-uncarboxylated matrix Gla protein (dp-ucMGP) by ELISA
decreases, 31% at 180 ug and 46% at 360 ug after 12 weeks; unchanged on placebo
Not recorded as a finding: this platform holds no node for the endpoint
Dp-ucMGP decreased significantly and dose-dependently in the 180 μg and 360 μg MK-7 supplementation groups (P time*treatment < 0.001) after 12 weeks, by 31% and 46% respectively, while dp-ucMGP levels remained unchanged after placebo treatment.
PMID 23062766 · one of two readings recorded this
circulating desphospho-uncarboxylated matrix Gla protein (dp-ucMGP), ELISA
decreases, 31% and 46% decrease at 180 and 360 μg
Not recorded as a finding: this platform holds no node for the endpoint
Dp-ucMGP decreased significantly and dose-dependently in the 180 μg and 360 μg MK-7 supplementation groups (P time*treatment < 0.001) after 12 weeks, by 31% and 46% respectively, while dp-ucMGP levels remained unchanged after placebo treatment.
PMID 23062766 · one of two readings recorded this
desphospho-carboxylated MGP and total uncarboxylated MGP, ELISA
no effect
Not recorded as a finding: no outcome node for dp-cMGP or t-ucMGP; sentence is agentless
Changes over time of dp-cMGP (p = 0.42) and t-ucMGP (p = 0.23) levels did not differ between treatment arms.
PMID 23062766 · one of two readings recorded this
desphospho-carboxylated MGP (dp-cMGP)
no effect, p = 0.42
Changes over time of dp-cMGP (p = 0.42) and t-ucMGP (p = 0.23) levels did not differ between treatment arms
PMID 23062766 · one of two readings recorded this
desphospho-uncarboxylated MGP (dp-ucMGP)
decreases, p = 0.001
Dp-ucMGP decreased significantly and dose-dependently in the 180 μg and 360 μg MK-7 supplementation groups (P time*treatment < 0.001) after 12 weeks, by 31% and 46% respectively
PMID 23062766 · one of two readings recorded this
desphospho-uncarboxylated MGP (dp-ucMGP)
decreases, p = 0.001
Dp-ucMGP decreased significantly and dose-dependently in the 180 μg and 360 μg MK-7 supplementation groups (P time*treatment < 0.001) after 12 weeks, by 31% and 46% respectively
PMID 23062766 · one of two readings recorded this
desphospho-uncarboxylated MGP (dp-ucMGP)
no effect
while dp-ucMGP levels remained unchanged after placebo treatment
PMID 23062766 · one of two readings recorded this
osteocalcin ratio ucOC:cOC, circulating, assay not stated
decreases, 60% at 180 μg, 74% at 360 μg
Not recorded as a finding: no outcome node for the ucOC:cOC ratio
The osteocalcin ratio also decreased significantly after 12-week supplementation with 180 μg (60%) and 360 μg (74%) MK-7 (P time*treatment < 0.001), while levels remained unchanged after placebo treatment.
PMID 23062766 · one of two readings recorded this
other cardiovascular risk factors
no effect
Other cardiovascular risk factors did not differ between treatments arms
PMID 23062766 · one of two readings recorded this
ratio of uncarboxylated osteocalcin to carboxylated osteocalcin (ucOC:cOC), proxy of vitamin K status
decreases, 60% (180 μg) and 74% (360 μg) decrease
Not recorded as a finding: No outcome node for the ucOC/cOC ratio.
The osteocalcin ratio also decreased significantly after 12-week supplementation with 180 μg (60%) and 360 μg (74%) MK-7 (P time*treatment < 0.001), while levels remained unchanged after placebo treatment.
PMID 23062766 · one of two readings recorded this
total uncarboxylated MGP (t-ucMGP)
no effect, p = 0.23
Changes over time of dp-cMGP (p = 0.42) and t-ucMGP (p = 0.23) levels did not differ between treatment arms
PMID 23062766 · one of two readings recorded this
ucOC/cOC ratio
decreases, p = 0.001
The osteocalcin ratio also decreased significantly after 12-week supplementation with 180 μg (60%) and 360 μg (74%) MK-7 (P time*treatment < 0.001)
PMID 23062766 · one of two readings recorded this
ucOC/cOC ratio
decreases, p = 0.001
The osteocalcin ratio also decreased significantly after 12-week supplementation with 180 μg (60%) and 360 μg (74%) MK-7 (P time*treatment < 0.001)
PMID 23062766 · one of two readings recorded this
serum MK-4 level after 7 days consecutive administration
no effect
Consecutive administration of MK-4 (60 μg; 135 nmol) or MK-7 (60 μg; 92 nmol) for 7 days demonstrated that MK-4 supplementation did not increase serum MK-4 levels
PMID 23140417 · one of two readings recorded this
serum MK-4 level after single dose
no effect
MK-4 was not detectable in the serum of all subjects at any time point
PMID 23140417 · one of two readings recorded this
serum MK-7 level after 7 days consecutive administration
increases
However, consecutive administration of MK-7 increased serum MK-7 levels significantly in all subjects
PMID 23140417 · one of two readings recorded this
serum MK-7 level after single and 7-day oral dosing, compared with MK-4
increases
Not recorded as a finding: this platform holds no node for the endpoint
However, consecutive administration of MK-7 increased serum MK-7 levels significantly in all subjects.
PMID 23140417 · one of two readings recorded this
serum MK-7 level after single dose and after 7 days of consecutive administration, compared with MK-4
increases
Not recorded as a finding: this platform holds no node for the endpoint
However, consecutive administration of MK-7 increased serum MK-7 levels significantly in all subjects.
PMID 23140417 · one of two readings recorded this
bone mineral content and density, femoral neck
increases
MK-7 intake significantly improved vitamin K status and decreased the age-related decline in BMC and BMD at the lumbar spine and femoral neck, but not at the total hip
PMID 23525894 · one of two readings recorded this
bone mineral content and density, lumbar spine
increases
MK-7 intake significantly improved vitamin K status and decreased the age-related decline in BMC and BMD at the lumbar spine and femoral neck, but not at the total hip
PMID 23525894 · one of two readings recorded this
bone mineral content and density, total hip
no effect
MK-7 intake significantly improved vitamin K status and decreased the age-related decline in BMC and BMD at the lumbar spine and femoral neck, but not at the total hip
PMID 23525894 · one of two readings recorded this
femoral neck bone strength indices
increases
Bone strength was also favorably affected by MK-7
PMID 23525894 · one of two readings recorded this
loss in vertebral height, lower thoracic region mid-site
decreases
MK-7 significantly decreased the loss in vertebral height of the lower thoracic region at the mid-site of the vertebrae
PMID 23525894 · one of two readings recorded this
vitamin K status (ucOC/cOC ratio)
increases
MK-7 intake significantly improved vitamin K status and decreased the age-related decline in BMC and BMD at the lumbar spine and femoral neck, but not at the total hip
PMID 23525894 · one of two readings recorded this
desphosphorylated-uncarboxylated matrix Gla protein (dp-uc-MGP), baseline and after 8 weeks, in chronic haemodialysis patients given MK-7 360, 720 or 1080 µg thrice weekly
decreases
Not recorded as a finding: the comparison was against another active treatment
MK-7 supplementation dose dependently reduced dp-uc-MGP.
PMID 24285428 · one of two readings recorded this
desphosphorylated-uncarboxylated MGP (dp-uc-MGP) at baseline and after 8 weeks of MK-7 360, 720 or 1080 µg thrice weekly (assay not named in the abstract)
decreases, dose-dependent reduction of dp-uc-MGP; no MK-7-free arm (dose-versus-dose design)
Not recorded as a finding: the comparison was against another active treatment
MK-7 supplementation dose dependently reduced dp-uc-MGP.
PMID 24285428 · one of two readings recorded this
dp-uc-MGP
decreases
MK-7 supplementation dose dependently reduced dp-uc-MGP.
PMID 24285428 · one of two readings recorded this
dp-uc-MGP
decreases, p = 0.023
At baseline, dp-uc-MGP was not associated with phylloquinone intake (P = 0.92), but correlated inversely with menaquinone intake (P = 0.023).
PMID 24285428 · one of two readings recorded this
dp-uc-MGP
no effect, p = 0.92
At baseline, dp-uc-MGP was not associated with phylloquinone intake (P = 0.92), but correlated inversely with menaquinone intake (P = 0.023).
PMID 24285428 · one of two readings recorded this
dp-uc-MGP
decreases
The levels decreased by 17, 33 and 46% in the respective groups.
PMID 24285428 · one of two readings recorded this
dp-uc-MGP
decreases
The levels decreased by 17, 33 and 46% in the respective groups.
PMID 24285428 · one of two readings recorded this
dp-uc-MGP
decreases
The levels decreased by 17, 33 and 46% in the respective groups.
PMID 24285428 · one of two readings recorded this
acute phase markers (IL-6, hsCRP, TNF-α) and endothelial dysfunction markers (VCAM, E-selectin, AGEs)
no effect
MK-7 decreased dp-ucMGP by 50 % compared to placebo, but did not influence the markers for acute phase and endothelial dysfunction
PMID 25694037 · one of two readings recorded this
carotid-femoral pulse wave velocity (cfPWV)
decreases
After three year MK-7 supplementation cfPWV and the Stiffness Index βsignificantly decreased in the total group
PMID 25694037 · one of two readings recorded this
circulating dp-ucMGP
decreases
MK-7 decreased dp-ucMGP by 50 % compared to placebo, but did not influence the markers for acute phase and endothelial dysfunction
PMID 25694037 · one of two readings recorded this
distension, compliance, distensibility, Young's Modulus and local carotid PWV (cPWV)
increases
distension, compliance, distensibility, Young's Modulus, and the local carotid PWV (cPWV) improved in women having a baseline Stiffness Index β above the median of 10.8
PMID 25694037 · one of two readings recorded this
Stiffness Index β
decreases
After three year MK-7 supplementation cfPWV and the Stiffness Index βsignificantly decreased in the total group
PMID 25694037 · one of two readings recorded this
C-reactive protein (CRP)
decreases
a significant decrease in MK-7 treated group for the levels of undercarboxylated osteocalcin (ucOC), erythrocyte sedimentation rate (ESR), disease activity score assessing 28 joints with ESR (DAS28-ESR), C-reactive protein (CRP) and matrix metalloproteinase (MMP-3) was found
PMID 26073022 · one of two readings recorded this
DAS28-ESR, C-reactive protein, ESR, ucOC and MMP-3 in RA patients
decreases
Not recorded as a finding: the result compares a group with itself, not with a control
In the cross sectional study, a significant decrease in MK-7 treated group for the levels of undercarboxylated osteocalcin (ucOC), erythrocyte sedimentation rate (ESR), disease activity score assessing 28 joints with ESR (DAS28-ESR), C-reactive protein (CRP) and matrix metalloproteinase (MMP-3) was found.
PMID 26073022 · one of two readings recorded this
disease activity score assessing 28 joints with ESR (DAS28-ESR)
decreases
a significant decrease in MK-7 treated group for the levels of undercarboxylated osteocalcin (ucOC), erythrocyte sedimentation rate (ESR), disease activity score assessing 28 joints with ESR (DAS28-ESR), C-reactive protein (CRP) and matrix metalloproteinase (MMP-3) was found
PMID 26073022 · one of two readings recorded this
erythrocyte sedimentation rate, DAS28-ESR, C-reactive protein, MMP-3 and undercarboxylated osteocalcin in RA patients
decreases, significant decrease in MK-7 treated group
Not recorded as a finding: the result compares a group with itself, not with a control
In the cross sectional study, a significant decrease in MK-7 treated group for the levels of undercarboxylated osteocalcin (ucOC), erythrocyte sedimentation rate (ESR), disease activity score assessing 28 joints with ESR (DAS28-ESR), C-reactive protein (CRP) and matrix metalloproteinase (MMP-3) was found.
PMID 26073022 · one of two readings recorded this
erythrocyte sedimentation rate (ESR)
decreases
a significant decrease in MK-7 treated group for the levels of undercarboxylated osteocalcin (ucOC), erythrocyte sedimentation rate (ESR), disease activity score assessing 28 joints with ESR (DAS28-ESR), C-reactive protein (CRP) and matrix metalloproteinase (MMP-3) was found
PMID 26073022 · one of two readings recorded this
matrix metalloproteinase-3 (MMP-3)
decreases
a significant decrease in MK-7 treated group for the levels of undercarboxylated osteocalcin (ucOC), erythrocyte sedimentation rate (ESR), disease activity score assessing 28 joints with ESR (DAS28-ESR), C-reactive protein (CRP) and matrix metalloproteinase (MMP-3) was found
PMID 26073022 · one of two readings recorded this
serum MK-7 level
increases
A marked increase in the levels of MK-7 for the moderate and good responders compared to non-responders was observed
PMID 26073022 · one of two readings recorded this
ucOC, ESR and DAS28-ESR decrease
decreases
a marked decrease in RA clinical and biochemical markers for moderate and good response compared to non-responders was observed in ucOC, ESR and DAS28-ESR
PMID 26073022 · one of two readings recorded this
undercarboxylated osteocalcin (ucOC)
decreases
a significant decrease in MK-7 treated group for the levels of undercarboxylated osteocalcin (ucOC), erythrocyte sedimentation rate (ESR), disease activity score assessing 28 joints with ESR (DAS28-ESR), C-reactive protein (CRP) and matrix metalloproteinase (MMP-3) was found
PMID 26073022 · one of two readings recorded this
carboxylated osteocalcin/undercarboxylated osteocalcin ratio, circulating, dose-dependent increase in Study 1
increases
Not recorded as a finding: No outcome node for the cOC/ucOC ratio; ucOC concentration node does not cover a ratio.
Menaquinone-7 increased the carboxylated osteocalcin/undercarboxylated osteocalcin ratio dose dependently, and significant effects were observed in both the 100 and 200 μg groups compared with the 0 μg group.
PMID 26875489 · one of two readings recorded this
carboxylated osteocalcin/undercarboxylated osteocalcin ratio
increases
Undercarboxylated osteocalcin concentrations decreased significantly, and the carboxylated osteocalcin/undercarboxylated osteocalcin ratio increased significantly in the 100 μg menaquinone-7 group compared with the placebo group (Study 2)
PMID 26875489 · one of two readings recorded this
carboxylated osteocalcin/undercarboxylated osteocalcin ratio
increases
Menaquinone-7 increased the carboxylated osteocalcin/undercarboxylated osteocalcin ratio dose dependently, and significant effects were observed in both the 100 and 200 μg groups compared with the 0 μg group
PMID 26875489 · one of two readings recorded this
carboxylated osteocalcin/undercarboxylated osteocalcin ratio
decreases
The carboxylated osteocalcin/undercarboxylated osteocalcin ratio decreased significantly from baseline in the 0 μg menaquinone-7 group
PMID 26875489 · one of two readings recorded this
carboxylated/undercarboxylated osteocalcin ratio, circulating, assay not stated
increases
Not recorded as a finding: no outcome node for the cOC/ucOC ratio
Undercarboxylated osteocalcin concentrations decreased significantly, and the carboxylated osteocalcin/undercarboxylated osteocalcin ratio increased significantly in the 100 μg menaquinone-7 group compared with the placebo group (Study 2).
PMID 26875489 · one of two readings recorded this
circulating carboxylated osteocalcin and undercarboxylated osteocalcin, and their cOC/ucOC ratio
decreases
Not recorded as a finding: this platform holds no node for the endpoint
Undercarboxylated osteocalcin concentrations decreased significantly, and the carboxylated osteocalcin/undercarboxylated osteocalcin ratio increased significantly in the 100 μg menaquinone-7 group compared with the placebo group (Study 2).
PMID 26875489 · one of two readings recorded this
circulating carboxylated osteocalcin / undercarboxylated osteocalcin ratio
increases, dose dependent; significant at 100 and 200 ug vs 0 ug
Not recorded as a finding: this platform holds no node for the endpoint
Menaquinone-7 increased the carboxylated osteocalcin/undercarboxylated osteocalcin ratio dose dependently, and significant effects were observed in both the 100 and 200 μg groups compared with the 0 μg group.
PMID 26875489 · one of two readings recorded this
undercarboxylated osteocalcin concentration
decreases
Undercarboxylated osteocalcin concentrations decreased significantly, and the carboxylated osteocalcin/undercarboxylated osteocalcin ratio increased significantly in the 100 μg menaquinone-7 group compared with the placebo group (Study 2)
PMID 26875489 · one of two readings recorded this
circulating dp-ucMGP
decreases
Circulating dp-ucMGP and ucOC were significantly lowered after consumption of the yogurt products and the MK-7 capsules, reflecting vitamin K status improvement
PMID 26908424 · one of two readings recorded this
circulating ucOC
decreases
Circulating dp-ucMGP and ucOC were significantly lowered after consumption of the yogurt products and the MK-7 capsules, reflecting vitamin K status improvement
PMID 26908424 · one of two readings recorded this
fasting plasma concentrations of various biomarkers, yogurt K versus yogurt Kplus
no effect
No significant differences in fasting plasma concentrations of various biomarkers between the yogurts were found
PMID 26908424 · one of two readings recorded this
increase in fasting plasma MK-7
increases
The increase in plasma MK-7 with the yogurt Kplus product was more pronounced than the increase in MK-7 with the capsules
PMID 26908424 · one of two readings recorded this
bone mineral density at any site (DXA)
no effect
There were no significant differences between the groups in HRpQCT-derived parameters at the radius or in BMD at any site
PMID 27625301 · one of two readings recorded this
HRpQCT-derived parameters at the radius
no effect
There were no significant differences between the groups in HRpQCT-derived parameters at the radius or in BMD at any site
PMID 27625301 · one of two readings recorded this
tibia trabecular number percent change (HRpQCT)
no effect
trabecular number in tibia was unchanged in the MK-7-group (-0.1 ± 1.9%) (mean ± s.d.) and decreased in the placebo group (-3.5 ± 2.2%)
PMID 27625301 · one of two readings recorded this
tibia trabecular spacing percent change (HRpQCT)
no effect
trabecular spacing was unchanged in the MK-7 group (+1.2 ± 8.0%) and increased in the placebo group (+4.5 ± 9.7%)
PMID 27625301 · one of two readings recorded this
tibia trabecular thickness percent change (HRpQCT)
no effect, p = 0.05
trabecular thickness was unchanged in the MK-7 group (+0.2 ± 1.7%) and increased in the placebo group (+4.0 ± 2.2%) (between-group changes for all: P < 0.05)
PMID 27625301 · one of two readings recorded this
tibial trabecular number, spacing and thickness by HRpQCT after 12 months in postmenopausal women with osteopenia
Not recorded as a finding: this platform holds no node for the endpoint
There were no significant differences between the groups in HRpQCT-derived parameters at the radius or in BMD at any site.
PMID 27625301 · one of two readings recorded this
undercarboxylated osteocalcin (ucOC) percent change
decreases, p = 0.01
ucOC decreased in the MK-7 group (-65.6 (59.1; 71.0) %) (median (CI)) compared with the placebo group (-6.4 (-13.5; 1.2) %) after 3 months (P < 0.01)
PMID 27625301 · one of two readings recorded this
heart-rate AUC
increases, p = 0.07
Vitamin K2 supplementation was associated with a 12% increase in maximal cardiac output, with P = .031, with a trend toward an increase in heart-rate AUC, with P = .070.
PMID 28646812 · one of two readings recorded this
maximal cardiac output during a graded cycle-ergometer exercise test, noninvasive skin-electrode cardiac output monitor; heart-rate and stroke-volume area under the curve
increases, 12% increase in maximal cardiac output with vitamin K2 vs rice-flour placebo, P = .031, p = 0.031
Not recorded as a finding: the paper never mentions the compound
Vitamin K2 supplementation was associated with a 12% increase in maximal cardiac output, with P = .031, with a trend toward an increase in heart-rate AUC, with P = .070.
PMID 28646812 · one of two readings recorded this
maximal cardiac output during a graded cycle ergometer test, noninvasive cardiac output from skin-mounted electrodes; also heart-rate AUC and stroke volume
increases, 12% increase in maximal cardiac output, P = .031, p = 0.031
Not recorded as a finding: the paper never mentions the compound
Vitamin K2 supplementation was associated with a 12% increase in maximal cardiac output, with P = .031, with a trend toward an increase in heart-rate AUC, with P = .070.
PMID 28646812 · one of two readings recorded this
maximal cardiac output
increases, p = 0.031
Vitamin K2 supplementation was associated with a 12% increase in maximal cardiac output, with P = .031, with a trend toward an increase in heart-rate AUC, with P = .070.
PMID 28646812 · one of two readings recorded this
stroke volume
no effect
No significant changes occurred in stroke volume.
PMID 28646812 · one of two readings recorded this
adherence (tablet count)
no effect, p = 0.05
No significant difference in adherence was found between groups: 90% (SD = 20) in the 200 μg vitamin K group, 82% (SD = 27) in the 400 μg vitamin K group, and 88% (SD = 33) in the placebo group (P >.05 for all comparisons).
PMID 31211416 · one of two readings recorded this
adverse events (any), 200 µg arm versus placebo and 400 µg arms
increases, more adverse events in the 200 µg arm than in the placebo or 400 µg arms
Not recorded as a finding: Reported for one dose arm only, with no proportion or test in the text (supplement only), so it is not a whole-trial estimate for CAT:outcome/supplement-adverse-event-incidence.
There were more adverse events in the 200‐μg arm than in the placebo or 400‐μg arms as shown in Supplementary Material S1.
PMID 31211416 · one of two readings recorded this
adverse events (gastrointestinal events and injuries)
more adverse events in the 200 µg arm than in the placebo or 400 µg arms
Not recorded as a finding: A dose stratum only (200 µg) with no statistical test in the text, and it counts events where supplement-adverse-event-incidence needs the proportion of participants and whether events were solicited.
There were more adverse events in the 200‐μg arm than in the placebo or 400‐μg arms as shown in Supplementary Material S1.
PMID 31211416 · one of two readings recorded this
anteroposterior postural sway at 12 months, AMTI AccuSway platform, feet together, eyes open and closed (primary endpoint)
no effect
Not recorded as a finding: No outcome node for postural sway, and the sentence names neither vitamin K2 nor an arm. Table 2 gives 200 µg vs placebo −0.19 cm (95% CI −0.68 to 0.30, p = .44) and 400 µg vs placebo 0.17 cm (−0.33 to 0.66, p = .50), baseline-adjusted.
No significant differences in AP sway were seen between groups at 12 months, either adjusted for baseline or adjusted for minimization variables.
PMID 31211416 · one of two readings recorded this
anteroposterior postural sway at 12 months, AMTI AccuSway sway platform, adjusted for baseline (primary outcome)
no effect, no significant between-group difference at 12 months, adjusted for baseline or for minimization variables
Not recorded as a finding: No outcome node for postural sway; the Results sentence is also agentless and does not name the compound.
No significant differences in AP sway were seen between groups at 12 months, either adjusted for baseline or adjusted for minimization variables.
PMID 31211416 · one of two readings recorded this
anteroposterior sway at 12 mo, adjusted for baseline
no effect, p = 0.44
Adjusted for baseline | 200 μg vs placebo | −.19 (−.68 to.30) |.44
PMID 31211416 · one of two readings recorded this
anteroposterior sway at 12 mo, adjusted for baseline
no effect, p = 0.5
400 μg vs placebo |.17 (−.33 to.66) |.50
PMID 31211416 · one of two readings recorded this
anteroposterior sway at 12 mo, adjusted for baseline
no effect, p = 0.14
200 μg vs 400 μg |.36 (−.11 to.83) |.14
PMID 31211416 · one of two readings recorded this
anteroposterior sway at 12 mo, fully adjusted
no effect, p = 0.69
Fully adjusted a | 200 μg vs placebo | −.09 (−.53 to.35) |.69
PMID 31211416 · one of two readings recorded this
anteroposterior sway at 12 mo, fully adjusted
no effect, p = 0.4
400 μg vs placebo |.19 (−.25 to.63) |.40
PMID 31211416 · one of two readings recorded this
anteroposterior sway at 12 mo, fully adjusted
no effect, p = 0.2
200 μg vs 400 μg |.28 (−.15 to.70) |.20
PMID 31211416 · one of two readings recorded this
anteroposterior sway at 12 mo, multiple imputation
no effect, p = 0.39
Multiple imputation a | 200 μg vs placebo | −.20 (−.66 to.26) |.39
PMID 31211416 · one of two readings recorded this
anteroposterior sway at 12 mo, multiple imputation
no effect, p = 0.88
400 μg vs placebo |.04 (−.44 to.51) |.88
PMID 31211416 · one of two readings recorded this
anteroposterior sway at 12 mo, multiple imputation
no effect, p = 0.31
200 μg vs 400 μg |.24 (−.22 to.67) |.31
PMID 31211416 · one of two readings recorded this
anteroposterior sway at 12 mo, repeated measures
no effect, p = 0.72
Repeated measures a | 200 μg vs placebo | −.07 (−.43 to.30) |.72
PMID 31211416 · one of two readings recorded this
anteroposterior sway at 12 mo, repeated measures
no effect, p = 0.66
400 μg vs placebo | −.08 (−.44 to.28) |.66
PMID 31211416 · one of two readings recorded this
anteroposterior sway at 12 mo, repeated measures
no effect, p = 0.93
200 μg vs 400 μg | −.02 (−.37 to.34) |.93
PMID 31211416 · one of two readings recorded this
blood pressure
no effect
No significant differences were seen between groups for other measures of sway, for blood pressure, or for measures of physical performance.
PMID 31211416 · one of two readings recorded this
dp-ucMGP
decreases
Dp‐ucMGP levels were significantly lower, however, in the 200 μg and 400 μg vitamin K2 groups than in the placebo group
PMID 31211416 · one of two readings recorded this
dp-ucMGP
decreases
Dp‐ucMGP levels were significantly lower, however, in the 200 μg and 400 μg vitamin K2 groups than in the placebo group
PMID 31211416 · one of two readings recorded this
dp-ucMGP
decreases
confirming that vitamin K was producing the expected dose‐dependent effect on this marker of vitamin K biological activity
PMID 31211416 · one of two readings recorded this
falls rate from monthly falls diaries
no effect, falls rate not significantly different from placebo; numerically higher in the 200 µg arm
Not recorded as a finding: No outcome node for falls rate; detailed estimates are only in the supplement.
The treatment groups did not show a statistically significantly different falls rate to placebo, although falls rates were higher in the 200‐μg arm.
PMID 31211416 · both readings recorded this
falls rate
no effect
The treatment groups did not show a statistically significantly different falls rate to placebo, although falls rates were higher in the 200‐μg arm.
PMID 31211416 · one of two readings recorded this
falls rate
increases
The treatment groups did not show a statistically significantly different falls rate to placebo, although falls rates were higher in the 200‐μg arm.
PMID 31211416 · one of two readings recorded this
health and social care costs per participant
increases
Costs were lowest over 1 year among participants randomized to the placebo group (mean cost = £764 per participant).
PMID 31211416 · one of two readings recorded this
health and social care costs per participant
decreases
Costs were lower among participants in the low‐dose vitamin K2 group, relative to high‐dose vitamin K2 (£896‐£902 vs £1033‐£1044).
PMID 31211416 · one of two readings recorded this
incremental costs and quality-adjusted life years (EQ5D-5L) relative to placebo
neither dose produced any improvement relative to placebo
Not recorded as a finding: A cost-effectiveness result with no health-related quality-of-life estimate in the text; the sentence negates only one tail ('any improvement').
Neither dose of vitamin K2 produced any improvement relative to placebo.
PMID 31211416 · one of two readings recorded this
incremental costs and quality-adjusted life years
no effect
Neither dose of vitamin K2 produced any improvement relative to placebo.
PMID 31211416 · one of two readings recorded this
Log10 Berg Balance Scale treatment effect at 12 mo
no effect, p = 0.31
Log10 Berg Balance Scale treatment effect a (95% CI) | 200 μg vs placebo |.00 (−.00 to.02) |.31
PMID 31211416 · one of two readings recorded this
Log10 Berg Balance Scale treatment effect at 12 mo
no effect, p = 0.8
400 μg vs placebo | −.00 (−.02 to.01) |.80
PMID 31211416 · one of two readings recorded this
Log10 Berg Balance Scale treatment effect at 12 mo
no effect, p = 0.2
200 μg vs 400 μg | −.01 (−.03 to.00) |.20
PMID 31211416 · one of two readings recorded this
Log10 Timed Up & Go Test treatment effect at 12 mo
no effect, p = 0.44
Log10 Timed Up & Go Test treatment effect a (95% CI) | 200 μg vs placebo |.02 (−.03 to.07) |.44
PMID 31211416 · one of two readings recorded this
Log10 Timed Up & Go Test treatment effect at 12 mo
no effect, p = 0.23
400 μg vs placebo |.03 (−.02 to.09) |.23
PMID 31211416 · one of two readings recorded this
Log10 Timed Up & Go Test treatment effect at 12 mo
no effect, p = 0.64
200 μg vs 400 μg |.01 (−.04 to.06) |.64
PMID 31211416 · one of two readings recorded this
other measures of postural sway
no effect
No significant differences were seen between groups for other measures of sway, for blood pressure, or for measures of physical performance.
PMID 31211416 · one of two readings recorded this
other sway measures (mediolateral sway, 95% ellipse, total path length), blood pressure (supine, OMRON HEM-705 oscillometric), and physical performance (Short Physical Performance Battery, Timed Up & Go, Berg Balance Scale)
no effect, no significant between-group differences
Not recorded as a finding: No node for sway, SPPB, Timed Up & Go or Berg Balance Scale. Blood pressure was taken supine, and CAT:outcome/office-systolic-blood-pressure requires seated readings. The sentence is agentless and does not name the compound.
No significant differences were seen between groups for other measures of sway, for blood pressure, or for measures of physical performance.
PMID 31211416 · one of two readings recorded this
other sway measures (mediolateral sway, 95% ellipse, total path length), supine office blood pressure by OMRON HEM-705, Short Physical Performance Battery, Timed Up & Go and Berg Balance Scale
no effect
Not recorded as a finding: No node for the sway, SPPB, Timed Up & Go or Berg measures; blood pressure was taken supine, which the office blood pressure nodes (seated) do not admit; and the sentence names neither vitamin K2 nor an arm.
No significant differences were seen between groups for other measures of sway, for blood pressure, or for measures of physical performance.
PMID 31211416 · one of two readings recorded this
quality-adjusted life years and incremental costs (EQ-5D-5L, ICECAP-O, health and social care costs)
Not recorded as a finding: The sentence is a one-sided negation about QALYs and cost-effectiveness, not an EQ-5D score, so health-related-quality-of-life cannot be anchored on it.
Neither dose of vitamin K2 produced any improvement relative to placebo.
PMID 31211416 · one of two readings recorded this
SPPB treatment effect at 12 mo
no effect, p = 0.63
SPPB treatment effect a (95% CI) | 200 μg vs placebo | −.2 (−1.1 to.7) |.63
PMID 31211416 · one of two readings recorded this
SPPB treatment effect at 12 mo
no effect, p = 0.37
400 μg vs placebo | −.4 (−1.3 to.5) |.37
PMID 31211416 · one of two readings recorded this
SPPB treatment effect at 12 mo
no effect, p = 0.66
200 μg vs 400 μg | −.2 (−1.1 to.7) |.66
PMID 31211416 · one of two readings recorded this
time to first fall
no effect
Time to first fall was also not significantly different from placebo in the treatment groups.
PMID 31211416 · one of two readings recorded this
unadjusted anteroposterior sway, baseline to 12 mo
Unadjusted anteroposterior sway, cm (SD) | Placebo | 2.74 (1.01) | 2.84 (1.35) | 2.75 (1.38)
PMID 31211416 · one of two readings recorded this
unadjusted anteroposterior sway, baseline to 12 mo
Vitamin K 200 μg | 2.95 (.88) | 3.01 (1.33) | 2.51 (1.02)
PMID 31211416 · one of two readings recorded this
unadjusted anteroposterior sway, baseline to 12 mo
Vitamin K 400 μg | 2.93 (1.21) | 2.67 (1.22) | 2.88 (1.20)
PMID 31211416 · one of two readings recorded this
unadjusted anteroposterior sway, baseline to 6 mo
Unadjusted anteroposterior sway, cm (SD) | Placebo | 2.74 (1.01) | 2.84 (1.35) | 2.75 (1.38)
PMID 31211416 · one of two readings recorded this
unadjusted anteroposterior sway, baseline to 6 mo
Vitamin K 200 μg | 2.95 (.88) | 3.01 (1.33) | 2.51 (1.02)
PMID 31211416 · one of two readings recorded this
unadjusted anteroposterior sway, baseline to 6 mo
Vitamin K 400 μg | 2.93 (1.21) | 2.67 (1.22) | 2.88 (1.20)
PMID 31211416 · one of two readings recorded this
unadjusted Berg Balance Scale (median), baseline to 12 mo
Unadjusted Berg Balance Scale (median, IQR) | Placebo | 50 [45‐53] | 51 [38‐53] | 52 [41‐54]
PMID 31211416 · one of two readings recorded this
unadjusted Berg Balance Scale (median), baseline to 12 mo
Vitamin K 200 μg | 48 [42‐53] | 52 [46‐54] | 50 [47‐54]
PMID 31211416 · one of two readings recorded this
unadjusted Berg Balance Scale (median), baseline to 12 mo
Vitamin K 400 μg | 48 [44‐54] | 47 [42‐54] | 49 [40‐54]
PMID 31211416 · one of two readings recorded this
unadjusted Berg Balance Scale (median), baseline to 6 mo
Unadjusted Berg Balance Scale (median, IQR) | Placebo | 50 [45‐53] | 51 [38‐53] | 52 [41‐54]
PMID 31211416 · one of two readings recorded this
unadjusted Berg Balance Scale (median), baseline to 6 mo
Vitamin K 200 μg | 48 [42‐53] | 52 [46‐54] | 50 [47‐54]
PMID 31211416 · one of two readings recorded this
unadjusted Berg Balance Scale (median), baseline to 6 mo
Vitamin K 400 μg | 48 [44‐54] | 47 [42‐54] | 49 [40‐54]
PMID 31211416 · one of two readings recorded this
unadjusted SPPB, baseline to 12 mo
Unadjusted SPPB (mean, SD) | Placebo | 7.7 (2.3) | 8.0 (2.7) | 7.9 (3.0)
PMID 31211416 · one of two readings recorded this
unadjusted SPPB, baseline to 12 mo
Vitamin K 200 μg | 7.4 (2.6) | 7.8 (2.7) | 7.8 (2.7)
PMID 31211416 · one of two readings recorded this
unadjusted SPPB, baseline to 12 mo
Vitamin K 400 μg | 7.1 (2.7) | 7.2 (2.8) | 6.7 (3.1)
PMID 31211416 · one of two readings recorded this
unadjusted SPPB, baseline to 6 mo
Unadjusted SPPB (mean, SD) | Placebo | 7.7 (2.3) | 8.0 (2.7) | 7.9 (3.0)
PMID 31211416 · one of two readings recorded this
unadjusted SPPB, baseline to 6 mo
Vitamin K 200 μg | 7.4 (2.6) | 7.8 (2.7) | 7.8 (2.7)
PMID 31211416 · one of two readings recorded this
unadjusted SPPB, baseline to 6 mo
Vitamin K 400 μg | 7.1 (2.7) | 7.2 (2.8) | 6.7 (3.1)
PMID 31211416 · one of two readings recorded this
unadjusted Timed Up & Go (median), baseline to 12 mo
Unadjusted Timed Up & Go (median, IQR) | Placebo | 12.9 [9.7‐17.1] | 9.9 [8.5‐16.2] | 11.2 [9.1‐17.2]
PMID 31211416 · one of two readings recorded this
unadjusted Timed Up & Go (median), baseline to 12 mo
Vitamin K 200 μg | 14.2 [9.2‐21.3] | 11.7 [8.4‐18.1] | 12.5 [8.9‐19.0]
PMID 31211416 · one of two readings recorded this
unadjusted Timed Up & Go (median), baseline to 12 mo
Vitamin K 400 μg | 14.1 [9.4‐20.4] | 12.9 [8.4‐17.9] | 13.3 [9.6‐18.7]
PMID 31211416 · one of two readings recorded this
unadjusted Timed Up & Go (median), baseline to 6 mo
Unadjusted Timed Up & Go (median, IQR) | Placebo | 12.9 [9.7‐17.1] | 9.9 [8.5‐16.2] | 11.2 [9.1‐17.2]
PMID 31211416 · one of two readings recorded this
unadjusted Timed Up & Go (median), baseline to 6 mo
Vitamin K 200 μg | 14.2 [9.2‐21.3] | 11.7 [8.4‐18.1] | 12.5 [8.9‐19.0]
PMID 31211416 · one of two readings recorded this
unadjusted Timed Up & Go (median), baseline to 6 mo
Vitamin K 400 μg | 14.1 [9.4‐20.4] | 12.9 [8.4‐17.9] | 13.3 [9.6‐18.7]
PMID 31211416 · one of two readings recorded this
dp-ucMGP concentration
decreases
MK-7 supplementation significantly reduced dp-ucMGP compared with placebo (-205.6 pmol/L; 95% CI: -255.8, -155.3 pmol/L)
PMID 31387121 · one of two readings recorded this
femoral arterial calcification, 18F-NaF PET target-to-background ratio; calcification mass on CT
TBR difference 0.25; 95% CI: -0.02, 0.51, p = 0.06
Not recorded as a finding: this platform holds no node for the endpoint
After the 6-mo intervention, TBR tended to increase in the MK-7 group compared with placebo (0.25; 95% CI: -0.02, 0.51; P = 0.06), although this was not significant.
PMID 31387121 · one of two readings recorded this
femoral arterial calcification, 18F-NaF PET target-to-background ratio
no effect, p = 0.06
TBR tended to increase in the MK-7 group compared with placebo (0.25; 95% CI: -0.02, 0.51; P = 0.06)
PMID 31387121 · one of two readings recorded this
femoral arterial calcification as 18F-NaF PET target-to-background ratio; CT calcification mass; serum dp-ucMGP
0.25; 95% CI: -0.02, 0.51, p = 0.06
Not recorded as a finding: this platform holds no node for the endpoint
After the 6-mo intervention, TBR tended to increase in the MK-7 group compared with placebo (0.25; 95% CI: -0.02, 0.51; P = 0.06), although this was not significant.
PMID 31387121 · one of two readings recorded this
log-transformed CT calcification mass
no effect, p = 0.18
Log-transformed CT calcification mass did not increase in the intervention group compared with placebo (0.50; 95% CI: -0.23, 1.36; P = 0.18)
PMID 31387121 · one of two readings recorded this
aortic calcification (Agatston score)
no effect
Agatston score was increased significantly both in vitamin K2 and control group at 1 year with no difference between groups.
PMID 31529295 · one of two readings recorded this
aortic calcification (Agatston score)
increases
Agatston score was increased significantly both in vitamin K2 and control group at 1 year with no difference between groups.
PMID 31529295 · one of two readings recorded this
aortic calcification (Agatston score)
increases
Agatston score was increased significantly both in vitamin K2 and control group at 1 year with no difference between groups.
PMID 31529295 · one of two readings recorded this
progression of aortic calcification, Agatston score on abdominal computed tomography at baseline and 12 months; also uncarboxylated MGP (uc-MGP) by ELISA at baseline, 3 and 12 months
no effect
Not recorded as a finding: this platform holds no node for the endpoint
Agatston score was increased significantly both in vitamin K2 and control group at 1 year with no difference between groups.
PMID 31529295 · one of two readings recorded this
uncarboxylated MGP (uc-MGP) by ELISA at randomization, 3 and 12 months; also aortic calcification by Agatston score on abdominal computed tomography at baseline and 12 months (no between-group difference)
decreases, significantly lower uc-MGP in the vitamin K2 group than in controls at 1 year, p = 0.03
Not recorded as a finding: a node exists but the paper states a different instrument or population
At 1 year, vitK2 group had significantly lower values of uc-MGP in comparison to controls (p = 0.03).
PMID 31529295 · one of two readings recorded this
uncarboxylated MGP (uc-MGP)
decreases, p = 0.03
At 1 year, vitK2 group had significantly lower values of uc-MGP in comparison to controls (p = 0.03)
PMID 31529295 · one of two readings recorded this
uncarboxylated MGP (uc-MGP)
increases
Furthermore, uc-MGP at 1 year was increased by 12% in the control group.
PMID 31529295 · one of two readings recorded this
uncarboxylated MGP (uc-MGP)
decreases, p = 0.005
After 3 months of treatment, uc-MGP values remained unchanged in the vitK2 group but after 1 year were reduced by 47% (p = 0.005)
PMID 31529295 · one of two readings recorded this
uncarboxylated MGP (uc-MGP)
no effect
After 3 months of treatment, uc-MGP values remained unchanged in the vitK2 group but after 1 year were reduced by 47% (p = 0.005)
PMID 31529295 · one of two readings recorded this
bone loss
no effect
VK2 supplementation in dose of 90 µg/day performed a significant effect on reducing bone loss in postmenopausal women, but in combination with calcium and vitamin D3 brought no additional effects
PMID 32060566 · one of two readings recorded this
cOC/ucOC ratio
increases, p = 0.001
Serum biomarkers cOC/ucOC ratio increased in the intervention groups (treatment × time, p < 0.001)
PMID 32060566 · one of two readings recorded this
femoral neck bone loss (BMD change) after 1 year, men and postmenopausal women analysed separately; serum carboxylated/undercarboxylated osteocalcin (cOC/ucOC) ratio
decreases, femoral neck bone loss lower in postmenopausal women in the two 90 µg groups pooled vs placebo (treatment × time p = 0.006); no effect in men, p = 0.006
Not recorded as a finding: the paper never mentions the compound
At the endpoint, the bone loss of femoral neck was significantly lower in postmenopausal women in the two 90 µg groups (treatment × time, p = 0.006) compared with placebo, but no effects in men.
PMID 32060566 · one of two readings recorded this
femoral neck bone loss (bone mineral density) over 1 year, measuring instrument not named in the abstract; also serum cOC/ucOC ratio
decreases, femoral neck bone loss significantly lower than placebo in postmenopausal women in the two 90 µg groups (treatment x time p = 0.006); no effect in men (subgroup result), p = 0.006
Not recorded as a finding: the paper never mentions the compound
At the endpoint, the bone loss of femoral neck was significantly lower in postmenopausal women in the two 90 µg groups (treatment × time, p = 0.006) compared with placebo, but no effects in men.
PMID 32060566 · one of two readings recorded this
femoral neck bone loss
no effect
At the endpoint, the bone loss of femoral neck was significantly lower in postmenopausal women in the two 90 µg groups (treatment × time, p = 0.006) compared with placebo, but no effects in men
PMID 32060566 · one of two readings recorded this
femoral neck bone loss
decreases, p = 0.006
At the endpoint, the bone loss of femoral neck was significantly lower in postmenopausal women in the two 90 µg groups (treatment × time, p = 0.006) compared with placebo, but no effects in men
PMID 32060566 · one of two readings recorded this